Not checkedNot checked for notices yet.
Abstract: Immunomodulation in Vascularized Composite Allotransplantation – Preliminary Results in a Non-human Primate Model with Tocilizumab
Zhi Yang Ng, MD, Alexandre G. Lellouch, MD, Matthew W. Defazio, BS and 4 more
Plastic and Reconstructive Surgery, Global Open · 2016
doi:10.1097/01.gox.0000502936.44843.57 (opens in a new tab)
We email you when a new notice or a question about this paper appears.
Abstract
INTRODUCTION: Tolerance in vascularized composite allotransplantation (VCA) remains elusive and patients are faced with a lifetime of immunosuppression and associated risks. Tocilizumab (anti-IL-6 receptor monoclonal antibody) is currently FDA approved for use in rheumatoid and idiopathic arthritis. It mitigates inflammation, reduces the incidence of GvHD, and is potentially pro-tolerogenic. We investigated the utility of a short course of tocilizumab in a non-human primate model (NHP) of facial VCA to achieve prolonged survival and/or tolerance. MATERIALS AND METHODS: VCAs were transplanted into MHC-mismatched NHPs (n=4) after induction with anti-thymocyte globulin. Post-operative maintenance consisted of triple immunosuppression (FK506, methylprednisolone, MMF) before further conditioning (irradiation, lymphocyte depletion) in preparation for co-stimulatory blockade-based donor bone marrow transplantation (DBMT) on POD 60. Tocilizumab was administered on the day of DBMT, and at weekly intervals thereafter for a total of 5 doses. Post-DBMT, the recipient was maintained on a tapering course of cyclosporine before complete withdrawal 28 days later. VCAs were assessed by serial clinical assessment and histopathology. Mixed chimerism in peripheral blood was monitored by flow cytometry and in vitro immunologic responses were assessed through mixed lymphocyte reaction (MLR) assays. RESULTS: Two recipients were euthanized within 2 weeks of DBMT due to neutropenic sepsis and post-transplant lymphoproliferative disorder but both VCAs remained viable up to experimental endpoint. M4515 (full MHC-mismatched recipient) has been off of all immunosuppression for 3 weeks without any evidence of rejection. M3815 (haplomatched) developed mixed chimerism transiently at 6 weeks after DBMT and corresponding MLR assays demonstrated decreased anti-donor responses; immunosuppression was then successfully withdrawn for a total of 5 weeks before rejection developed. Although the rejection episode could be reversed with steroid bolus and a tapering course of FK506, recurrence occurred after another 2 weeks off immunosuppression. CONCLUSION: As with the clinical experience with tocilizumab, vigilant monitoring is required following drug administration due to increased susceptibility to neutropenia and infections1. Tocilizumab appears to promote engraftment after DBMT to allow short-medium term immunosuppression-free VCA survival across haplomatched barriers in this NHP model. Continued follow-up is required to determine if similar results can be achieved across a full MHC mismatch. Further studies in our laboratory are focused on optimizing the current protocol to achieve stable engraftment and durable mixed chimerism for tolerance of VCA. DISCLOSURE/FINANCIAL SUPPORT:Supported by the Reconstructive Transplantation Research Consortium grant W81XWH-13-2-0062. None of the authors has a financial interest in any of the products, devices, or drugs mentioned in this manuscript. REFERENCES: 1. Jones G, Sebba A, Gu J, Lowenstein MB, Calvo A, Gomez-Reino JJ, et al. Comparison of tocilizumab monotherapy versus methotrexate monotherapy in patients with moderate to severe rheumatoid arthritis: the AMBITION study. Ann Rheum Dis. 2010;69:88–96
Abstract licence: CC BY-NC-ND
Reads
Read by people on this page
None yet.
Checked or read by AI through naulon
None yet.
A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.
Are you an author?
Is this your paper?
Claim it to add your note and be paid when agents cite it. Free.